2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A – Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine)

References

• 1. Savoie N, Booth BP, Bradley T et al. The 2nd Calibration and Validation Group Workshop on Recent Issues in Good Laboratory Practice Bioanalysis. Bioanalysis (2009).
  Google Scholar
• 2. Savoie N, Garofolo F, Van Amsterdam P et al. 2009 White Paper on Recent Issues in Regulated Bioanalysis from the 3rd Calibration and Validation Group Workshop. Bioanalysis. 2(1), (2010).
  Google Scholar
• 3. Savoie N, Garofolo F, Van Amsterdam P et al. 2010 White Paper on Recent Issues in Regulated Bioanalysis & Global Harmonization of Bioanalytical Guidance. Bioanalysis. 2(12), (2010).
  Google Scholar
• 4. Garofolo F, Rocci ML, Dumont I et al. 2011 White Paper on Recent Issues in Bioanalysis and Regulatory Findings From Audits and Inspections. Bioanalysis (2011).
  Google Scholar
• 5. Desilva B, Garofolo F, Rocci M et al. 2012 White Paper on Recent Issues in Bioanalysis and Alignment of Multiple Guidelines. Bioanalysis. 4(18), (2012).
  Google Scholar
• 6. Stevenson L, Garofolo F, Desilva B et al. 2013 White Paper on Recent Issues in Bioanalysis: “Hybrid” – The Best of LBA and LCMS. Bioanalysis. 5(23), (2013).
  Google Scholar
• 7. Fluhler E, Hayes R, Garofolo F et al. 2014 White Paper on Recent Issues in Bioanalysis: A Full Immersion in Bioanalysis (Part 1-Small Molecules by LCMS). In: Bioanalysis (2014).
  Google Scholar
• 8. Dufield D, Neubert H, Garofolo F et al. 2014 White Paper on Recent Issues in Bioanalysis: A Full Immersion in Bioanalysis (Part 2-Hybrid LBA/LCMS, ELN & Regulatory Agencies' Input). In: Bioanalysis (2014).
  Google Scholar
• 9. Stevenson L, Amaravadi L, Myler H et al. 2014 White Paper on Recent Issues in Bioanalysis: A Full Immersion in Bioanalysis (Part 3-LBA and Immunogenicity). Bioanalysis. 6(24), (2014).
  Google Scholar
• 10. Welink J, Fluhler E, Hughes N et al. 2015 White Paper on Recent Issues in Bioanalysis: Focus on New Technologies and Biomarkers (Part 1-Small Molecules by LCMS). Bioanalysis. 7(22), (2015).
  Google Scholar
• 11. Ackermann B, Neubert H, Hughes N et al. 2015 White Paper on Recent Issues in Bioanalysis: Focus on New Technologies and Biomarkers (Part 2 - Hybrid LBA/LCMS and Input from Regulatory Agencies). Bioanalysis. 7(23), (2015).
  Google Scholar
• 12. Amaravadi L, Song A, Myler H et al. 2015 White Paper on Recent Issues in Bioanalysis: Focus on New Technologies and Biomarkers (Part 3-LBA, Biomarkers and Immunogenicity). In: Bioanalysis (2015).
  Google Scholar
• 13. Yang E, Welink J, Cape S et al. 2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV) (Part 1 - Small Molecules, Peptides and Small Molecule Biomarkers by LCMS). Bioanalysis 8(22), (2016).
  Google Scholar
• 14. Song A, Lee A, Garofolo F et al. 2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV): (Part 2 - Hybrid LBA/LCMS and Input From Regulatory Agencies). Bioanalysis. 8(23), (2016).
  Google Scholar
• 15. Richards S, Amaravadi L, Pillutla R et al. 2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV): (Part 3 - LBA, Biomarkers and Immunogenicity). Bioanalysis. 8(23), (2016).
  Google Scholar
• 16. Welink J, Yang E, Hughes N et al. 2017 White Paper on Recent Issues in Bioanalysis: Aren't BMV Guidance/Guidelines “Scientific”? (Part 1 - LCMS: Small Molecules, Peptides and Small Molecule Biomarkers). Bioanalysis. 9(22), (2017).
  Google Scholar
• 17. Neubert H, Song A, Lee A et al. 2017 White Paper on Recent Issues in Bioanalysis: Rise of Hybrid LBA/LCMS Immunogenicity Assays (part 2: Hybrid LBA/LCMS Biotherapeutics, Biomarkers & Immunogenicity Assays and Regulatory Agencies' Inputs). Bioanalysis. 9(23), (2017).
  Google Scholar
• 18. Gupta S, Richards S, Amaravadi L et al. 2017 White Paper on Recent Issues in Bioanalysis: A Global Perspective on Immunogenicity Guidelines & Biomarker Assay Performance (Part 3-LBA: Immunogenicity, Biomarkers and PK Assays). In: Bioanalysis (2017).
  Google Scholar
• 19. Welink J, Xu Y, Yang E et al. 2018 White Paper on Recent Issues in Bioanalysis: “A Global Bioanalytical Community Perspective on Last Decade of Incurred Samples Reanalysis (ISR)” (Part 1-Small Molecule Regulated Bioanalysis, Small Molecule Biomarkers, Peptides & Oligonucleotide Bioanalysis). Bioanalysis. 10(22), (2018).
  Google Scholar
• 20. Neubert H, Olah T, Lee A et al. 2018 White Paper on Recent Issues in Bioanalysis: Focus on Immunogenicity Assays by Hybrid LBA/LCMS and Regulatory Feedback Part 2 - PK, PD & ADA Assays by Hybrid LBA/LCMS & Regulatory Agencies' Inputs on Bioanalysis, Biomarkers and Immunogenicity. In: Bioanalysis (2018).
  Google Scholar
• 21. Stevenson L, Richards S, Pillutla R et al. 2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on BAV (Part 3 – LBA/Cell-Based Assays: Immunogenicity, Biomarkers and PK Assays). Bioanalysis. 10(24), 1973–2001 (2018).
  CASGoogle Scholar
• 22. Garofolo W, Savoie N. The Decennial Index of the White Papers in Bioanalysis: ‘A Decade of Recommendations (2007–2016)’. Bioanalysis [Internet]. 9(21), 1681–1704 (2017). Available from: https://doi.org/10.4155/bio-2017-4979
  Google Scholar
• 23. Fandozzi C, Evans C, Wilson A et al. 2019 White Paper on Recent Issues in Bioanalysis: Chromatographic Assays (part 1 - Innovation in Small Molecules and Oligonucleotides & Mass Spectrometric Method Development Strategies for Large Molecule Bioanalysis). In: Bioanalysis (2019).
  Google Scholar
• 24. Booth B, Stevenson L, Pillutla R et al. 2019 White Paper on Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (Part 2-Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity). In: Bioanalysis (2019).
  MedlineGoogle Scholar
• 25. Piccoli S, Mehta D, Vitaliti A et al. 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3-Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62). In: Bioanalysis. Future Medicine Ltd., 2207–2244 (2019).
  Google Scholar
• 26. Spitz S, Zhang Y, Fischer S et al. 2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (Part 2A - Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine). Bioanalysis. 13(5), (2021).
  Google Scholar
• 27. Corsaro B, Yang T, Murphy R et al. 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 – Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays). Bioanalysis. 13(6), 415–463 (2021).
  CASGoogle Scholar
• 28. Neubert H, Alley SC, Lee A et al. 2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome (Part 1 - Recommendations on Industry/Regulators Consensus on BMV of Biotherapeutics by LCMS, Advanced Application in Hybrid Assays, Regulatory Challenges in Mass Spec, Innovation in Small Molecules, Peptides and Oligos). Bioanalysis. 13(4), (2021).
  Google Scholar
• 29. Hersey S, Keller S, Mathews J et al. 2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (Part 2 – Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation). Bioanalysis. 14(10), 627–692 (2022).
  CASGoogle Scholar
• 30. Loo L, Harris S, Milton M et al. 2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization). Bioanalysis. 14(11), 737–793 (2022).
  CASGoogle Scholar
• 31. Kaur S, Alley SC, Szapacs M et al. 2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & C. Bioanalysis. 14(9), 505–580 (2022).
  CASGoogle Scholar
• 32. Sips L, Ediage EN, Ingelse B, Verhaeghe T, Dillen L. LCMS Quantification of Oligonucleotides in Biological Matrices with SPE or Hybridization Extraction. Bioanalysis. 11(21), (2019).
  Google Scholar
• 33. Darmon P, Dadoun F, Frachebois C et al. On the Meaning of Low-Dose ACTH(1-24) Tests to Assess Functionality of the Hypothalamic-Pituitary-Adrenal axis. Eur J Endocrinol. 140(1), (1999).
  MedlineGoogle Scholar
• 34. Alía P, Villabona C, Giménez O, Sospedra E, Soler J, Navarro MA. Profile, Mean Residence Time of ACTH and Cortisol Responses after Low and Standard ACTH Tests in Healthy Volunteers. Clin Endocrinol (Oxf). 65(3), (2006).
  MedlineGoogle Scholar
• 35. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Safety Testing of Drug Metabolites Guidance for Industry. https://www.fda.gov/media/72279/download (2020).
  Google Scholar
• 36. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2). https://database.ich.org/sites/default/files/M3_R2__Guideline.pdf (2009).
  Google Scholar
• 37. Mu R, Yuan J, Huang Y et al. Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics. Bio Drugs 36(2), (2022).
  Google Scholar
• 38. Huang Y, Mou S, Wang Y, Mu R, Liang M, Rosenbaum AI. Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM. Anal Chem. 93(15), (2021).
  Google Scholar
• 39. Baillie TA, Dalvie D, Rietjens IMCM, Cyrus Khojasteh S. Biotransformation and Bioactivation Reactions – 2015 Literature Highlights. Drug Metab Rev 48(2), (2016).
  MedlineGoogle Scholar
• 40. Hall MP, Gegg C, Walker K et al. Ligand-Binding Mass Spectrometry to Study Biotransformation of Fusion Protein Drugs and Guide Immunoassay Development: Strategic Approach and Application to Peptibodies Targeting the Thrombopoietin Receptor. AAPS Journal. 12(4), (2010).
  MedlineGoogle Scholar
• 41. Rautio J, Kumpulainen H, Heimbach T et al. Prodrugs: Design and Clinical Applications. Nat Rev Drug Discov 7(3), (2008).
  MedlineGoogle Scholar
• 42. Perez HL, Knecht D, Busz M. Overcoming Challenges Associated with the Bioanalysis of an Ester Prodrug and its Active Acid Metabolite. Bioanalysis. 9(20), (2017).
  Google Scholar
• 43. Mu R, Huang Y, Bouquet J et al. Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination. Anal Chem. 94(43), (2022).
  Google Scholar
• 44. Loo YM, McTamney PM, Arends RH et al. The SARS-CoV-2 Monoclonal Antibody Combination, AZD7442, is Protective in Nonhuman Primates and has an Extended Half-Life in Humans. Sci Transl Med. 14(635), (2022).
  Google Scholar
• 45. Leney AC, Heck AJR. Native Mass Spectrometry: What is in the Name? J Am Soc Mass Spectrom. 28(1), (2017).
  Google Scholar
• 46. Zhang L, Vasicek LA, Hsieh S, Zhang S, Bateman KP, Henion J. Top-down LCMS Quantitation of Intact Denatured and Native Monoclonal Antibodies in Biological Samples. Bioanalysis. 10(13), (2018).
  Google Scholar
• 47. Carle K, Kellie JF, Gunn GR, Jiang Y. Determination of Label Efficiency and Label Degree of Critical Reagents by LCMS and Native MS. Anal Biochem. 664 (2023).
  Google Scholar
• 48. Carr SA, Abbatiello SE, Ackermann BL et al. Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-Based Assay Development Using a Fit-For-Purpose Approach. Molecular and Cellular Proteomics. 13(3), (2014).
  Google Scholar
• 49. She X, Zou C, Zheng Z. Differences in Vitreous Protein Profiles in Patients With Proliferative Diabetic Retinopathy Before and After Ranibizumab Treatment. Front Med (Lausanne). 9 (2022).
  Google Scholar
• 50. Ogata S, Masuda T, Ito S, Ohtsuki S. Targeted Proteomics for Cancer Biomarker Verification and Validation. In: Cancer Biomarkers (2022).
  MedlineGoogle Scholar
• 51. Bognár Z, Gyurcsányi RE. Aptamers Against Immunoglobulins: Design, Selection and Bioanalytical Applications. Int J Mol Sci 21(16), (2020).
  Google Scholar
• 52. Baba T, Campbell JL, Le Blanc JCY, Hager JW, Thomson BA. Electron Capture Dissociation in a Branched Radio-Frequency Ion Trap. Anal Chem. 87(1), (2015).
  Google Scholar
• 53. Li P, Dupuis JF, Vrionis V, Mekhssian K, Magee T, Yuan L. Validation and Application of Hybridization Liquid Chromatography-Tandem Mass Spectrometry Methods for Quantitative Bioanalysis of Antisense Oligonucleotides. Bioanalysis. 14(9), (2022).
  Google Scholar
• 54. Brown CR, Gupta S, Qin J et al. Investigating the Pharmacodynamic Durability of GalNAc-siRNA Conjugates. Nucleic Acids Res. 48(21), (2021).
  Google Scholar
• 55. Huang Y, Del Nagro CJ, Balic K et al. Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate. Anal Chem. 92(16), (2020).
  Google Scholar
• 56. Faria M, Peay M, Lam B et al. Multiplex LCMS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody Against HER-2. Antibodies. 8(1), (2019).
  MedlineGoogle Scholar
• 57. Lanshoeft C, Stutz G, Elbast W et al. Analysis of Small Molecule Antibody-Drug Conjugate Catabolites in Rat Liver and Tumor Tissue by Liquid Extraction Surface Analysis Micro-Capillary Liquid Chromatography/Tandem Mass Spectrometry. Rapid Communications in Mass Spectrometry. 30(7), (2016).
  MedlineGoogle Scholar
• 58. Toby TK, Fornelli L, Kelleher NL. Progress in Top-Down Proteomics and the Analysis of Proteoforms. Annual Review of Analytical Chemistry 9 (2016).
  Google Scholar
• 59. Kotapati S, Deshpande M, Jashnani A, Thakkar D, Xu H, Dollinger G. The Role of Ligand-Binding Assay and LCMS in the Bioanalysis of Complex Protein and Oligonucleotide Therapeutics. Bioanalysis 13(11), (2021).
  Google Scholar
• 60. Wei C, Zhang G, Clark T et al. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma. Anal Chem. 88(9), (2016).
  Google Scholar
• 61. Lassman ME, Chappell DL, McAvoy T et al. Experimental Medicine Study to Measure Immune Checkpoint Receptors PD-1 and GITR Turnover Rates In Vivo in Humans. Clin Pharmacol Ther. 109(6), (2021).
  Google Scholar
• 62. Briggs RJ, Nicholson R, Vazvaei F et al. Method Transfer, Partial Validation, and Cross Validation: Recommendations for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS Journal. 16(6), (2014).
  MedlineGoogle Scholar
• 63. Stegemann S, Sheehan L, Rossi A et al. Rational and Practical Considerations to Guide a Target Product Profile for Patient-Centric Drug Product Development with Measurable Patient Outcomes – A Proposed Roadmap. European Journal of Pharmaceutics and Biopharmaceutics 177 (2022).
  MedlineGoogle Scholar
• 64. Bower J, Zimmer J, McCown S et al. Recommendations for the Content and Management of Certificates of Analysis for Reference Standards from the GCC for Bioanalysis. Bioanalysis. bio-2021-0046 (2021).
  Google Scholar
• 65. international Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Bioanalytical Method Validation and Study Sample AnalysiS M10. https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf (2022).
  Google Scholar
• 66. Nehls C, Buonarati M, Cape S et al. GCC Consolidated Feedback to ICH on the 2019 ICH M10 Bioanalytical Method Validation Draft Guideline. Bioanalysis. 11(18s), 1–228 (2019).
  CASGoogle Scholar
• 67. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product Guidance for Industry. https://www.fda.gov/media/88622/download (2016).
  Google Scholar
• 68. Obianom ON, Okusanya OO, Earp J, Thway TM. A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity Studies. Clin Pharmacol Ther. 108(1), (2020).
  MedlineGoogle Scholar
• 69. Obianom ON, Thway TM, Schrieber SJ et al. Retrospective Analysis of Bioanalytical Method Validation Approaches in Biosimilar Biological Product Development. AAPS Journal. 21(6), (2019).
  MedlineGoogle Scholar
• 70. Thway TM, Wang YM, Booth BP, Maxfield K, Huang SM, Zineh I. Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product Development. AAPS Journal. 22(1), (2020).
  Google Scholar
• 71. U.S. Department of Health and Human ServicesFood and Drug AdministrationCenter for Drug Evaluation and Research (CDER). Evaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101760391-pdf (2019).
  Google Scholar
• 72. Mercer TR, Xu J, Mason CE, Tong W. The Sequencing Quality Control 2 Study: Establishing Community Standards for Sequencing in Precision Medicine. Genome Biol 22(1), (2021).
  Google Scholar
• 73. Jones W, Gong B, Novoradovskaya N et al. A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency. Genome Biol. 22(1), (2021).
  Google Scholar
• 74. Willey JC, Morrison TB, Austermiller B et al. Advancing NGS Quality Control to Enable Measurement of Actionable Mutations in Circulating Tumor DNA. Cell Reports Methods. 1(7), (2021).
  MedlineGoogle Scholar
• 75. Gong B, Li D, Kusko R et al. Cross-oncopanel Study Reveals High Sensitivity and Accuracy with Overall Analytical Performance Depending on Genomic Regions. Genome Biol. 22(1), (2021).
  Google Scholar
• 76. Deveson IW, Gong B, Lai K et al. Evaluating the Analytical Validity of Circulating Tumor DNA Sequencing Assays for Precision Oncology. Nat Biotechnol. 39(9), (2021).
  MedlineGoogle Scholar
• 77. Zhang Y, Blomquist TM, Kusko R et al. Deep Oncopanel Sequencing Reveals Within Block Position-Dependent Quality Degradation in FFPE Processed Samples. Genome Biol. 23(1), (2022).
  Google Scholar
• 78. Prior S, Metcalfe C, Hufton SE, Wadhwa M, Schneider CK, Burns C. Maintaining ‘Standards’ for Biosimilar Monoclonal Antibodies. Nat Biotechnol 39(3), (2021).
  MedlineGoogle Scholar
• 79. Ohtsu Y, Tanaka S, Igarashi H et al. Analytical Method Validation for Biomarkers as a Drug Development Tool: Points to Consider. Bioanalysis. 13(18), (2021).
  Google Scholar
• 80. Guinn D, Madabushi R, Wang YM, Brodsky E, Zineh I, Maxfield K. Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation. Ther Innov Regul Sci. 54(6), (2020).
  Google Scholar
• 81. Shankar G, Arkin S, Cocea L et al. Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides - Harmonized Terminology and Tactical Recommendations. AAPS Journal 16(4), (2014).
  Google Scholar
• 82. Myler H, Pedras-Vasconcelos J, Phillips K et al. Anti-drug Antibody Validation Testing and Reporting Harmonization. AAPS Journal. 24(1), (2022).
  MedlineGoogle Scholar
• 83. Lamberth K, Reedtz-Runge SL, Simon J et al. Post Hoc Assessment of the Immunogenicity of Bioengineered Factor VIIa Demonstrates the use of Preclinical Tools. Sci Transl Med. 9(372), (2017).
  MedlineGoogle Scholar
• 84. Simhadri VL, McGill J, McMahon S, Wang J, Jiang H, Sauna ZE. Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population. Mol Ther Methods Clin Dev. 10 (2018).
  Google Scholar
• 85. Simhadri VL, Hopkins L, McGill JR et al. Cas9-Derived Peptides Presented by MHC Class II that Elicit Proliferation of CD4+ T-cells. Nat Commun. 12(1), (2021).
  MedlineGoogle Scholar
• 86. Tang XZE, Tan SX, Hoon S, Yeo GW. Pre-Existing Adaptive Immunity to the RNA-editing Enzyme Cas13d in Humans. Nat Med. 28(7), (2022).
  Google Scholar
• 87. Charlesworth CT, Deshpande PS, Dever DP et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 25(2), (2019).
  MedlineGoogle Scholar
• 88. Wagner DL, Peter L, Schmueck-Henneresse M. Cas9-Directed Immune Tolerance in Humans—A Model to Evaluate Regulatory T cells in Gene Therapy? Gene Ther 28(9), (2021).
  MedlineGoogle Scholar
• 89. Morais P, Adachi H, Yu YT. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Front Cell Dev Biol 9 (2021).
  Google Scholar
• 90. Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. N1-methylpseudouridine-incorporated mRNA Outperforms Pseudouridine-incorporated mRNA by Providing Enhanced Protein Expression and Reduced Immunogenicity in Mammalian Cell Lines and Mice. Journal of Controlled Release. 217 (2015).
  Google Scholar
• 91. Poolman J, Frasch C, Nurkka A, Käyhty H, Biemans R, Schuerman L. Impact of the Conjugation Method on the Immunogenicity of Streptococcus Pneumoniae Serotype 19F Polysaccharide in Conjugate Vaccines. Clinical and Vaccine Immunology. 18(2), (2011).
  Google Scholar
• 92. Valentini S, Santoro G, Baffetta F et al. Monocyte-activation Test to Reliably Measure the Pyrogenic Content of a Vaccine: An In Vitro Pyrogen Test to Overcome In Vivo Limitations. Vaccine. 37(29), (2019).
  MedlineGoogle Scholar
• 93. Shibata H, Nishimura K, Maeda T et al. Evaluation of the Analytical Performance of Anti-SARS-CoV-2 Antibody Test Kits Distributed or Developed in Japan. Bioanalysis. 14(6), (2022).
  Google Scholar
• 94. Furuta-Hanawa B, Yamaguchi T, Uchida E. Two-Dimensional Droplet Digital PCR as a Tool for Titration and Integrity Evaluation of Recombinant Adeno-Associated Viral Vectors. Hum Gene Ther Methods. 30(4), (2019).
  MedlineGoogle Scholar